AstraZeneca PLC (AZN) annual results, year to 31 December 2023: revenue USD 45,811 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2023 it reported revenue of USD 45,811 million, up 3.3% on the year before. Its profit attributable to shareholders was USD 5,955 million, up 81.1%, and diluted earnings per share USD 3.81.
The year to 31 December 2023, against the year before
| Year to | Dec 2022 | Dec 2023 |
|---|---|---|
| Revenue | 44,351 | 45,811 |
| Cost of sales | 12,391 | 8,268 |
| Gross profit | 31,960 | 37,543 |
| Research and development | 9,762 | 10,935 |
| Selling, general and administrative | 18,419 | 19,216 |
| Operating profit | 3,757 | 8,193 |
| Finance costs | 1,346 | 1,626 |
| Profit before tax | 2,501 | 6,899 |
| Income tax | -792 | 938 |
| Profit for the year | 3,293 | 5,961 |
| Profit attributable to shareholders | 3,288 | 5,955 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2022 | Dec 2023 |
|---|---|---|
| Cash from operations | 9,808 | 10,345 |
| Purchase of property, plant and equipment | 1,091 | 1,361 |
| Free cash flow | 8,717 | 8,984 |
| Dividends paid | 4,364 | 4,481 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2022 | Dec 2023 |
|---|---|---|
| Total assets | 96,483 | 101,119 |
| Equity attributable to shareholders | 37,037 | 39,143 |
| Cash and cash equivalents | 6,166 | 5,840 |
| Borrowings, as filed | 29,232 | 28,622 |
| Lease liabilities | 953 | 1,128 |
| Trade and other receivables | 10,521 | 12,126 |
| Inventories | 4,699 | 5,424 |
| Goodwill | 19,820 | 20,048 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2022 | Dec 2023 |
|---|---|---|
| Gross margin | 72.1% | 82.0% |
| Operating margin | 8.5% | 17.9% |
| Net margin | 7.4% | 13.0% |
| Free cash flow margin | 19.7% | 19.6% |
| Return on year-end equity | 8.9% | 15.2% |
| Effective tax rate | -31.7% | 13.6% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023, this page
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2023, filed 24 February 2026, accession 0001104659-26-019130: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.